Date post: | 05-Apr-2018 |
Category: |
Documents |
Upload: | domas-prita |
View: | 243 times |
Download: | 0 times |
of 18
7/31/2019 APLIKASI HASIL UJI KLINIK
1/18
APLIKASI HASIL UJI KLINIK
Ruben Dharmawan
Laboratorium Parasitologi danMikologi FKUNS
7/31/2019 APLIKASI HASIL UJI KLINIK
2/18
Clinical Scenario
You are the attending physician on duty when apoor 45 year old man presents to theemergency room of a general hospital in the
Philippines. He has experienced severe chestpain for two hours, associated with clammyperspiration. Physical examination reveals ablood pressure of 110/70 mmHg, a heart rateof 92, a normal 1st heart sound and clearlungs. An electrocardiogram discloses 3mmST segment elevation in the inferior leads.
7/31/2019 APLIKASI HASIL UJI KLINIK
3/18
As intravenous lines are placed, and the patientis prepared for admission to the coronary
care unit, you consider whether you shouldoffer this patient a thrombolytic agent.Though your response is that the
impecunious patient cannot afford thetreatment, you ponder the right course ofaction in a richer patient. As your duty endsthat night, you resolve to prepare for the next
patient admitted for an acute myocardialinfarction (MI), by retrieving the bestevidence on the use of thrombolytics.
7/31/2019 APLIKASI HASIL UJI KLINIK
4/18
Biologic Issues
1.Are there pathophysiologicdifferences in the illness under study
that may lead to a diminished treatmentresponse?
2.Are there patient differences thatmay diminish the treatment response?
7/31/2019 APLIKASI HASIL UJI KLINIK
5/18
Social and Economic Issues
1.Are there important differences inpatient compliance that may diminish
the treatment response?
2.Are there important differences in
provider compliance that may diminishthe treatment response?
7/31/2019 APLIKASI HASIL UJI KLINIK
6/18
Epidemiologic Issues
1.Do my patients have co-morbidconditions that significantly alter the
potential benefits and risks of thetreatment?
2.Are there important differences in
untreated patients' risk of adverseoutcomes that might alter the efficiencyof treatment?
7/31/2019 APLIKASI HASIL UJI KLINIK
7/18
1.Are there pathophysiologic differences in the
illness under study that may lead to a
diminished treatment response?
a. Divergence in pathogenetic mechanisms.
Contoh : Orang Negro responsif terhadapdiuretik tetapi tidak responsif terhadap beta-
blocker.
b. Biologic Differences in the causative agent.Contoh : Malaria dengan variasi resistensi
terhadap obat.
7/31/2019 APLIKASI HASIL UJI KLINIK
8/18
2.Are there patient differences that may
diminish the treatment response?a. Differences in drug metabolism.
Slow metabolizers vs rapid
metabolizers.Hepatic N-acetyl transferase tinggipada orang Asia sehingga kadar
isoniazid, hydralazine danprocainamide.
G-6-PDH terhadap sulfonamide.
7/31/2019 APLIKASI HASIL UJI KLINIK
9/18
b. Differences in immune response.
Hemophilus influenza vaccine has alower efficacy in Alaskan natives than innon-native populations.
c. Environmental factors.
Thyroid dysfunction differs in low
versus high iodine environments.
7/31/2019 APLIKASI HASIL UJI KLINIK
10/18
3.Are there important differences in
patient compliance that may diminishthe treatment response?
a. Resource limitations in a particularsetting.
b. Less obvious attitudinal or behavioralidiosyncrasies.
patient compliance.
7/31/2019 APLIKASI HASIL UJI KLINIK
11/18
4.Are there important differences in
provider compliance that may diminishthe treatment response?
Meliputi perlengkapan dan peralatandiagnostik, monitoring, interventionserta ketrampilan ahli medis/teknisi.
Contoh : walaupun rheumatic atrialfibrillation cukup banyak ditemukan dinegara2 Asia, hanya sedikitlaboratorium mampu melakukan testitrasi dosis warfarin.
7/31/2019 APLIKASI HASIL UJI KLINIK
12/18
7/31/2019 APLIKASI HASIL UJI KLINIK
13/18
b. Competing etiologies of outcome.
Di Filipina di suatu RS angka kematiansetelah pemberian streptokinase padaAMI tinggi karena ternyata banyakpenderita disertai pneumonia withsepsis.
Infark berat sering disertai atrialfibrilasi, bila diberi antikoagulan(warfarin) akan memperolehkeuntungan ganda.
7/31/2019 APLIKASI HASIL UJI KLINIK
14/18
6.Are there important differences in
untreated patients' risk of adverseoutcomes that might alter the efficiencyof treatment?
NNT = Number Needed to Treat
RR = Relative Risk
RRR = Relative Risk ReductionARR = Absolute Risk Reduction
7/31/2019 APLIKASI HASIL UJI KLINIK
15/18
NNT = jumlah pasien yang perlu diobatiagar terdapat 1 efek samping =treatments efficiency = kebalikan dari
ARR.
Resiko tanpa terapi = 20%
RRR 10% maka resiko jadi 18%
Tiap 100 pasien ada pencegahan 2 (2%)
Maka NNT = 100/2 = 50Jika Resiko tanpa terapi 10%, RRR tetapi
10% maka NNT 100.
7/31/2019 APLIKASI HASIL UJI KLINIK
16/18
Contoh :
Age standardized mortality rate for CHDdi Jepang = 40/100.000
North Ireland = 414/100.000
10 x penurunan insidens menyebabkan10 x kenaikan NNT obat pencegahkematian akibat CHD 10 kalipenurunan efisiensi pengobatan
Reconsideration of applying the resultsof a trial to low risk patients.
7/31/2019 APLIKASI HASIL UJI KLINIK
17/18
DISCUSSION
RESOLUTION
7/31/2019 APLIKASI HASIL UJI KLINIK
18/18
TERIMA
KASIH